Brief: Xbrane Submits BLA For Ranibizumab Biosimilar Candidate To FDA

Xbrane Biopharma AB

24/04/2023 06:12

April 24 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * XBRANE SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO
FDA
    * EXPECTS A 10 MONTH REVIEW PROCESS AND HENCE AN APPROVAL
COULD
TAKE PLACE DURING FIRST HALF OF 2024

Source text for Eikon:  ID:nMFN2p4Wsp 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))